ArticleInternational journal of molecular sciences2026
Immunohistochemical Analysis of pH-Sensitive TRPV5 in Common Skin Tumors.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transient receptor potential vanilloid 5 (TRPV5) is a calcium- and pH-sensitive ion channel. It plays a role in tumor biology and cellular calcium homeostasis. Due to the inverse pH gradient in solid tumors (extracellular acidosis and increased intracellular pH), TRPV5 is interesting as a signaling molecule in tumors, as the altered pH in the tumor microenvironment (TME) impacts tumor growth and metastasis. This is the first study to analyze the expression of TRPV5 in common skin cancers, i.e., basal cell carcinomas (BCC), squamous cell carcinomas (SCC), malignant melanomas (MM) and melanocytic nevi (MCN). The results showed a significantly lower expression of TRPV5 in BCC than in all other tumor entities analyzed. While less than half of the BCC were positive for TRPV5, SCC, MM, and MCN exhibited a high level of positive staining results. These results suggest that TRPV5 may especially help as a novel marker in the differentiation of SCC from BCC. The low expression of TRPV5 in BCC, a rarely metastatic tumor, may also point to a role of TRPV5 in the progression of epithelial skin tumors. Further functional studies, however, are needed to clarify the exact role of TRPV5 in skin tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.